PENTIXAPHARM HOLDING N AG (PTP) - Total Liabilities
Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has total liabilities worth €10.04 Million EUR (≈ $11.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PTP cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PENTIXAPHARM HOLDING N AG - Total Liabilities Trend (2021–2025)
This chart illustrates how PENTIXAPHARM HOLDING N AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PENTIXAPHARM HOLDING N AG assets under control.
PENTIXAPHARM HOLDING N AG Competitors by Total Liabilities
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ado Optronics
TWO:3516
|
Taiwan | NT$1.23 Billion |
|
Pancontinental Energy NL
AU:PCL
|
Australia | AU$580.18K |
|
Werewolf Therapeutics Inc
NASDAQ:HOWL
|
USA | $7.86 Million |
|
Health In Tech, Inc. Class A Common Stock
NASDAQ:HIT
|
USA | $7.36 Million |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr13.56 Million |
|
Shuang-Bang Industrial
TWO:6506
|
Taiwan | NT$1.23 Billion |
|
Toro Energy Ltd
AU:TOE
|
Australia | AU$946.70K |
|
Vishnu Prakash R Punglia Limited
NSE:VPRPL
|
India | Rs12.39 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down PENTIXAPHARM HOLDING N AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of PENTIXAPHARM HOLDING N AG to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PENTIXAPHARM HOLDING N AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual total liabilities of PENTIXAPHARM HOLDING N AG from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €6.79 Million ≈ $7.93 Million |
-62.24% |
| 2024-12-31 | €17.97 Million ≈ $21.01 Million |
-27.87% |
| 2023-12-31 | €24.92 Million ≈ $29.13 Million |
+61.69% |
| 2022-12-31 | €15.41 Million ≈ $18.02 Million |
+1119.15% |
| 2021-12-31 | €1.26 Million ≈ $1.48 Million |
-- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more